STOCK TITAN
  1. Home
  2. Sec-filings
  3. RYTM
  4. [Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity

Rhythm Pharmaceuticals (RYTM) director granted RSUs, stock options and converts RSUs to shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

RHYTHM PHARMACEUTICALS director Stuart A. Arbuckle reported equity-based compensation and an option exercise. He received 2,324 restricted stock units (RSUs) and stock options for 3,691 shares of common stock at an exercise price of $107.55 per share, expiring on June 23, 2036. He also exercised 4,712 RSUs into 4,712 shares of common stock, bringing his direct common stock holdings to 11,712 shares. The new RSUs and options generally vest in full by June 24, 2027, subject to continued service.

Positive

  • None.

Negative

  • None.
Insider Arbuckle Stuart A
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,691 $0.00 --
Grant/Award Restricted Stock Units 2,324 $0.00 --
Exercise Restricted Stock Units 4,712 $0.00 --
Exercise Common Stock 4,712 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,691 shares (Direct, null); Restricted Stock Units — 2,324 shares (Direct, null); Common Stock — 11,712 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units are fully vested. The restricted stock units have no expiration date. The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
RSU grant 2,324 units Restricted Stock Units granted on June 24, 2026
Option grant shares 3,691 shares Stock options granted on June 24, 2026
Option exercise price $107.55 per share Conversion/exercise price for stock options
Option expiration June 23, 2036 Expiration date of newly granted stock options
RSUs exercised 4,712 units RSUs converted into common stock on June 23, 2026
Common shares after exercise 11,712 shares Direct common stock holdings after RSU conversion
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 107.5500."
Exercise or conversion of derivative security financial
"Transaction code M is described as Exercise or conversion of derivative security."
fully vested financial
"The restricted stock units are fully vested."
expiration date financial
"The options fully vest and have an expiration date of 2036-06-23."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Arbuckle Stuart A
(Last)(First)(Middle)
C/O RHYTHM PHARMACEUTICALS, INC.
222 BERKELEY STREET, 12TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/23/2026M4,712A(1)11,712D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)06/23/2026M4,712 (2) (2)Common Stock4,712$00D
Stock Option (right to buy)$107.5506/24/2026A3,691 (3)06/23/2036Common Stock3,691$03,691D
Restricted Stock Units(1)06/24/2026A2,324 (4) (4)Common Stock2,324$02,324D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
2. The restricted stock units are fully vested. The restricted stock units have no expiration date.
3. The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.
4. The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
/s/ Stephen Vander Stoep, attorney-in-fact for Stuart A. Arbuckle06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Stuart Arbuckle receive in this RYTM Form 4 filing?

Stuart Arbuckle received 2,324 restricted stock units and stock options for 3,691 shares of Rhythm Pharmaceuticals common stock. These awards are compensation grants, not open-market purchases, and give him future rights to acquire or receive company shares under specified terms.

What is the exercise price and expiration date of Stuart Arbuckle’s new RYTM stock options?

The newly granted stock options cover 3,691 shares at an exercise price of $107.55 per share and expire on June 23, 2036. Arbuckle can choose to exercise these options after vesting, paying the exercise price to receive common shares.

How many Rhythm Pharmaceuticals shares does Stuart Arbuckle hold after these transactions?

After these transactions, Stuart Arbuckle directly holds 11,712 shares of common stock in Rhythm Pharmaceuticals. This total reflects the conversion of 4,712 vested restricted stock units into common shares reported in the filing as a derivative exercise transaction.

What happened to the 4,712 restricted stock units mentioned in the RYTM Form 4?

The 4,712 restricted stock units were exercised and converted into 4,712 shares of common stock. Following this derivative exercise transaction, the filing shows the RSU position at zero, indicating those particular units have fully settled into common shares.

When do Stuart Arbuckle’s new Rhythm Pharmaceuticals RSUs and options vest?

The footnotes state the new RSUs and options fully vest on the earlier of June 24, 2027 or immediately before Rhythm’s next 2027 annual stockholder meeting. Vesting is conditioned on Arbuckle’s continued service with the company through the applicable vesting date.